The Evolving BCMA Bispecific Landscape in Relapsed or Refractory Myeloma

Dr Paul Richardson and Dr Hans Lee frame the rapidly evolving treatment landscape for patients with relapsed or refractory multiple myeloma who are triple-class exposed to proteasome inhibitors, immunomodulatory agents, and anti-CD38 antibodies. The discussion highlights how historically limited options for this high-risk population have expanded dramatically over the past several years with the emergence of T-cell–redirecting therapies, including BCMA-directed CAR T-cell therapies and bispecific antibodies. Drs Richardson and Lee emphasize BCMA as a validated therapeutic target across multiple modalities, from antibody-drug conjugates to bispecific antibodies and cellular therapies. The conversation also introduces linvoseltamab as the newest BCMA-directed bispecific antibody, with early reflections on its tolerability and safety profile. Together, the faculty set the foundation for a deeper exploration of efficacy, safety, and real-world integration of BCMA-directed bispecific therapies in contemporary myeloma practice.